Before we get into the specifics of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), we want to draw your attention to a micro cap company that is flying under the radar on solid news. OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) today announced the signing of a non-binding term sheet (“Term Sheet”) with NYSE-listed Teva Pharmaceuticals Industries Ltd. (“Teva”), the world’s largest generic medicines producer, with regards to Norepinefrine for the Mexican market. This registration can as well be used in other Central and Latin American countries and will be selected by own discretion. Read more HERE.
We are going to take a close look at Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today’s focus will be a fundamental evaluation of the stock from top to bottom.
As such, let’s start with the top line: Revenue trends.
Last quarter, the company saw its overall sales move to 40,031 in total revenues. That represents an overall change in revenues, on a quarterly year/year basis, of -0.9%. If we translate that into sequential terms, the company saw sales decline by 0% from quarter to quarter.
While revenue analysis gives us a strong sense of changing demand trends in the company’s end market, and how the company is executing in terms of its relationship with potential customers, real shareholder value is only truly created by profitability.
With this in mind, we turn to the company’s bottom line data.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is intriguing when broken down to its core data. The cost of selling goods last quarter was 488,377, yielding a gross basic income of (448,346). For shareholders, given the total diluted outstanding shares of 40.17M, this means an overall earnings per share of (0.28). Note, this compares with a consensus analyst forecast of -0.16 in earnings per share for its next fiscal quarterly report.
Next, lets look ahead at coming performance based on what analysts are projecting for the company more generally, before closing with a survey of the balance sheet and cash flow.
At present, analysts hold a consensus average recommendation of Buy. This is based on a total of 6. While we don’t suggest taking analyst recommendations as face value plans for action in a portfolio, we do think it is important to note where consensus is on a stock to understand what basic assumptions are perhaps already discounted into market pricing of shares of the stock.
As far as price targets, analysts currently have an average target on shares of at 14.43. In addition, if we turn to next year, we see estimates of a fiscal year forecast to bring about -0.49 in total earnings per share. On a median price to earnings ratio basis, that outlook adds up to a valuation of 9,999 times earnings.
So far, we have covered how the company is doing on both the top and bottom line, as well as what professional analysts believe about its core trends and operational and financial performance going forward. However, we would be remiss if we did not also take a quick look at cash flows and the company’s balance sheet to round out our perspective on the name.
As the reader is no doubt aware, for any company, balance sheet health sits at the heart of the company’s capacity to stand up to the demands and obligations incurred by normal and contingent operations, which in turn lies at the core of a company’s ability to retain the faith of investors in the marketplace. For NASDAQ: AUPH, the company presently holds about 53.17M in cash in the coffers. That cash is balanced against about - in total current liabilities.
It’s important to consider both a static and dynamic picture, particularly where debt levels are concerned. This means, we need to take into account any trends. In this case, the company’s debt has been growing. The company also has 76.44M in total assets, balanced by 28.23M in total liabilities, which suggests where this story might go under adverse economic or financial conditions.
As far as cash flows, the company saw a free cash flow last quarter of (5.63M), representing a quarterly net change in cash of 36.18M. On a net operating level, the company saw about (5.62M) in cash flow.
We will update the interesting story of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) as new events transpire.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:
The Next Big Thing In Biotech?https://journaltranscript.com
Get our top rated alerts on the biotech sector
A new field of medicine needs attentionhttps://journaltranscript.com
Here are the reasons to invest in CMXC
Traders Need To Know This Nowhttps://journaltranscript.com
WallStreet is loading up on this stock. Find out why